Blog

AHFS Patient Medication Information Update – May 2016

The May update to the AHFS Patient Medication Information (PMI) database has been published. Highlights of the update include:

New PMI Monographs:

  • Amphotericin B Liposomal Injection (AmBisome®)
    • Amphotericin B liposomal injection is used to treat fungal infections such as cryptococcal meningitis and visceral leishmaniasis
  • Dexamethasone Injection (Decadron® & Available generically)
    • Dexamethasone injection is used to treat severe allergic reactions, certain types of edema, gastrointestinal disease, and certain types of arthritis, and other diseases treated by corticosteroids
  • Reslizumab Injection (Cinqair®)
    • Reslizumab injection is used along with other medications to treat asthma

FDA MedWatch Alerts – Monograph Revisions

  • Aripiprazole
    • Warning regarding compulsive or uncontrollable urges to gamble, binge eat, shop, and have sex have been reported
  • Ticagrelor and Vortioxetine
    • Brand name change for vortioxetine (Brintellix) due to name confusion with ticagrelor (Brilinta)
  • Olanzapine and Olanzapine injection
    • Rare, but serious skin reactions
  • Fluoroquinolones
    • Serious adverse effects generally outweigh benefits for patients with sinusitis, bronchitis, and uncomplicated UTIs
    • Affected monographs:
      • Ciprofloxacin, ciprofloxacin injection, gemifloxacin, levofloxacin, levofloxacin injection, moxifloxacin, moxifloxacin injection, ofloxacin

Visit AHFS at MLA: Mosaic 16 in Toronto!

If you’re attending MLA: Mosaic 16, May 13th – 18th in Toronto, visit the ASHP booth, #726, and get an exclusive preview of AHFS Clinical Drug Information, the next big thing for easy access to real-time drug information and updates.

Sign up for more information about AHFS Clinical Drug Information and other ASHP products for institutions, and register for a chance to win a Fitbit Charge HR!

fitbit

AHFS Drug Information/Essentials Update – May 2016

The May update to the AHFS Drug Information/Essentials database was published today. Highlights from this month’s update include:

New AHFS/Essentials Monographs

  • Ganciclovir (Zirgan®)
    • The ophthalmic gel is indicated for the topical treatment of acute herpetic keratitis in patients with dendritic ulcers

FDA MedWatch Alerts

  • Metformin
    • Revised warnings in reduced kidney function
  • Fluconazole
    • FDA is evaluating the results of a Danish study that concluded there is a possible increased risk of miscarriage with the use of oral fluconazole for yeast infections
  • Aripiprazole
    • Warning regarding compulsive or uncontrollable urges to gamble, binge eat, shop, and have sex have been reported
  • Ticagrelor and Vortioxetine
    • Brand name change for vortioxetine (Brintellix) due to name confusion with ticagrelor (Brilinta)
1 10 11 12 13 14